查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2130813

非侵入性血糖監測市場分析及至2035年預測：類型、產品、技術、組件、應用、設備、最終用戶、功能、解決方案

Non Invasive Glucose Monitoring Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Device, End User, Functionality, Solutions
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球非侵入性血糖監測市場預計將從2025年的4.075億美元成長到2035年的6.432億美元，複合年成長率（CAGR）為4.6%。全球非侵入性血糖監測市場仍處於新興技術領域，主要政府機構尚未發布專門針對該領域的標準化全球市場規模或複合年成長率預測。糖尿病患者人數的增加以及數位化血糖監測的日益普及推動了市場需求。根據美國疾病管制與預防中心（CDC）估計，截至2023年，美國有4,010萬人被診斷出患有或未被診斷患有糖尿病，另有1.152億成年人處於糖尿病前期。此外，美國食品藥物管理局（FDA）的最新進展表明，互聯血糖監測技術正在不斷進步，例如Biolinq Shine自主「目標範圍內時間」微型感測器和非處方血糖監測系統。這些進步正在推動人們對更便捷的監測方法的需求。

光學血糖監測利用近紅外線、中紅外線、拉曼光譜和光子感測等技術，透過組織和皮膚估算血糖濃度；而電磁系統則利用無線電波、微波或電磁相互作用分析與血糖相關的變化。光學方法受益於小型化光電、光譜學、訊號處理和人工智慧的進步，而電磁平台則專注於感測器整合和非接觸式測量。兩種技術的目標都是避免指尖穿刺，減少對侵入式感測器的依賴。由於光學系統與穿戴式裝置的兼容性，目前在研發和商業化領域備受關注。隨著開發人員不斷檢驗其準確性、校準穩定性、干擾校正和臨床有效性，其成長前景仍然強勁。

市場區隔
類型 光學血糖監測、經皮血糖監測、酵素法血糖監測等。
產品 穿戴式裝置、非穿戴式裝置、連續血糖監測儀等。
科技 近紅外線光譜、中紅外線光譜、拉曼光譜、光聲光譜、螢光技術等。
成分 感測器、發送器、接收器、軟體及其他
目的 糖尿病管理、血糖值監測及其他服務。
裝置 智慧型手錶、智慧型貼片、攜帶式裝置及其他
最終用戶 醫院、居家照護、診斷中心及其他
功能 即時監測、間歇監測等。
解決方案 數據管理解決方案、遠端監控解決方案等。

即時監測透過連網設備持續估算血糖值，並提供動態測量、警報、趨勢資訊和數位化分析，從而支援糖尿病和代謝性疾病的預防性管理。間歇性監測則按預設時間間隔或根據使用者操作測量血糖值，從而可能減少監測頻率並簡化設備結構。隨著使用者越來越需要持續追蹤與用餐、運動、用藥和日常生活相關的血糖值波動，即時功能的重要性日益凸顯。 FDA 批准的數位血糖監測技術表明，連網監測領域的監管活動正在不斷擴大。隨著感測器體積的縮小和演算法的改進，無需皮膚穿刺即可進行更頻繁的測量，非侵入性監測領域有望進一步發展。

區域概覽

北美在非侵入性血糖監測領域保持著強勁的發展勢頭，這得益於其先進的醫療設備基礎設施、大規模的糖尿病管理生態系統、強大的研發能力以及完善的血糖監測技術保險報銷系統。美國擁有良好的監管和商業化環境，FDA 正在積極批准連網血糖監測系統。該地區對便利的家用和穿戴式血糖監測設備的需求也十分旺盛。根據美國疾病管制與預防中心 (CDC) 的報告顯示，糖尿病患者、糖尿病前期患者以及一些希望了解自身代謝狀況的消費者正在擴大使用連續血糖監測儀。對生物技術、數位健康、臨床研究和監管發展的大力投資預計將繼續推動該領域的商業化進程。

在歐洲，隨著醫療保健系統將預防醫學、數位健康、以患者為中心的監測和糖尿病管理置於優先地位，巨大的商業機會正在湧現。穿戴式血糖監測技術的普及得益於完善的醫療保健基礎設施、對數位健康日益成長的投資以及對更便捷監測方式的需求。歐洲的技術開發商也在推動感測器小型化、光譜學、生物感測和基於人工智慧的數據分析，從而建構下一代非侵入式平台的生態系統。互聯醫療模式和遠端患者監護的擴展有望改善血糖檢驗設備、智慧型手機、醫療專業人員和數位療法之間的協作。儘管監管合規性和臨床有效性仍然是重要的考慮因素，但醫療保健數位化進程的推進以及對持續代謝資訊日益成長的需求預計將推動市場的長期發展。

主要趨勢和促進因素

非接觸式血糖監測技術的興起：

市場正朝著穿戴式、人工智慧賦能的非接觸式血糖感測方向發展，並將血糖監測整合到更廣泛的數位健康生態系統中。開發人員正在將先進的光學和電磁感測技術與機器學習、微型電子元件、智慧型手機連接和雲端分析相結合，以提高測量頻率和用戶便利性。 FDA資料庫顯示，穿戴式和連網血糖監測技術持續獲得批准，顯示該技術正不斷發展。長遠來看，發展方向是製造更小巧、更微創的設備，這些設備能夠提供連續的代謝訊息，同時減少對傳統指尖採血和植入式感測方法的依賴。

對無針糖尿病管理的需求日益成長：

糖尿病負擔日益加重，以及人們對便利血糖管理的需求不斷成長，是推動非侵入性監測技術投資的主要動力。根據美國疾病管制與預防中心（CDC）估計，美國有4,010萬人患有糖尿病（已確診或未確診），另有1.152億成年人處於糖尿病前期。這為尋求更便利的血糖監測方式創造了龐大的潛在客戶群。消費者和醫療專業人員越來越重影片繁的血糖值訊息，以便了解治療效果、飲食模式、身體活動和代謝變化。現有持續血糖監測（CGM）設備的廣泛應用也顯示了對自動化監測的需求，而感測器、無線連接、人工智慧演算法和穿戴式電子設備的進步，正使向完全非侵入性平台的過渡變得越來越現實。

目錄

第1章：執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 光學血糖監測
    • 經皮血糖監測
    • 基於酵素的血糖監測
    • 其他
  • 市場規模及預測：依產品分類
    • 穿戴式裝置
    • 非穿戴式裝置
    • 持續血糖監測
    • 其他
  • 市場規模及預測：依技術分類
    • 近紅外線光譜
    • 中紅外線光譜
    • 拉曼光譜
    • 光聲光譜學
    • 螢光技術
    • 其他
  • 市場規模及預測：依組件分類
    • 感應器
    • 發送器
    • 接收器
    • 軟體
    • 其他
  • 市場規模及預測：依應用領域分類
    • 糖尿病管理
    • 血糖值測量
    • 其他
  • 市場規模及預測：依設備分類
    • 智慧型手錶
    • 智慧型貼片
    • 手持裝置
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 居家醫療
    • 診斷中心
    • 其他
  • 市場規模及預測：功能
    • 即時監控
    • 間歇性監測
    • 其他
  • 市場規模及預測：按解決方案分類
    • 資料管理解決方案
    • 遠端監控解決方案
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 大公司的策略

第8章：公司簡介

  • Abbott Laboratories
  • Dexcom
  • Medtronic
  • Roche
  • Senseonics
  • GlucoTrack
  • Nemaura Medical
  • Integrity Applications
  • C8 MediSensors
  • DiaMonTech
  • Echo Therapeutics
  • GlySens
  • NovioSense
  • Biolinq
  • Afon Technology
  • PKvitality
  • POCTech
  • HemoCue
  • LifeScan
  • Ascensia Diabetes Care

第9章 關於我們

簡介目錄
Product Code: GIS11041

The global Non Invasive Glucose Monitoring Market is projected to grow from $407.5 Million in 2025 to $643.2 Million by 2035, at a compound annual growth rate (CAGR) of 4.6%. The global non-invasive glucose monitoring market remains an emerging technology segment, and major government agencies do not publish a standardized global market-size or CAGR estimate specifically for this category. Demand is supported by the expanding diabetes population and increasing acceptance of digital glucose monitoring. The CDC estimates that 40.1 million people in the United States had diagnosed or undiagnosed diabetes in 2023, while 115.2 million adults had prediabetes. FDA activity also indicates continued development of connected glucose technologies, including the Biolinq Shine autonomous time-in-range microsensor and OTC glucose-monitoring systems. These developments reinforce demand for less burdensome monitoring approaches.

Optical glucose monitoring uses techniques such as near-infrared, mid-infrared, Raman spectroscopy, and photonic sensing to estimate glucose concentrations through tissue or skin, while electromagnetic systems analyze glucose-related changes using radiofrequency, microwave, or electromagnetic interactions. Optical approaches benefit from advances in miniaturized photonics, spectroscopy, signal processing, and artificial intelligence, whereas electromagnetic platforms emphasize sensor integration and contactless measurement. Both technologies aim to eliminate finger-pricking and reduce dependence on invasive sensors. Optical systems currently attract substantial research and commercialization interest because of their compatibility with wearable formats. Growth prospects remain strong as developers improve accuracy, calibration stability, interference compensation, and clinical validation.

Market Segmentation
TypeOptical Glucose Monitoring, Transdermal Glucose Monitoring, Enzymatic Glucose Monitoring, Others
ProductWearable Devices, Non-Wearable Devices, Continuous Glucose Monitors, Others
TechnologyNear-Infrared Spectroscopy, Mid-Infrared Spectroscopy, Raman Spectroscopy, Photoacoustic Spectroscopy, Fluorescence Technology, Others
ComponentSensors, Transmitters, Receivers, Software, Others
ApplicationDiabetes Management, Blood Glucose Testing, Others
DeviceSmart Watches, Smart Patches, Handheld Devices, Others
End UserHospitals, Home Care Settings, Diagnostic Centers, Others
FunctionalityReal-Time Monitoring, Intermittent Monitoring, Others
SolutionsData Management Solutions, Remote Monitoring Solutions, Others

Real-time monitoring continuously estimates glucose levels and delivers dynamic readings, alerts, trend information, and digital insights through connected devices, supporting proactive diabetes and metabolic management. Intermittent monitoring captures glucose measurements at defined intervals or on user initiation, offering lower monitoring intensity and potentially simpler device architectures. Real-time functionality is gaining importance because users increasingly seek continuous visibility into glucose responses associated with meals, exercise, medication, and daily routines. FDA-authorized digital glucose-monitoring technologies demonstrate expanding regulatory activity in connected monitoring. The non-invasive segment is expected to develop further as sensor miniaturization and algorithms enable more frequent measurements without skin penetration.

Geographical Overview

North America maintains a strong position in non-invasive glucose monitoring development because of its advanced medical-device infrastructure, large diabetes-management ecosystem, substantial R&D capabilities, and established reimbursement pathways for glucose-monitoring technologies. The United States provides an important regulatory and commercialization environment, with the FDA maintaining extensive authorization activity for connected glucose-monitoring systems. The region also benefits from significant demand for convenient home-based and wearable monitoring. The CDC reports that continuous glucose monitors are increasingly available to people with diabetes, prediabetes, and some consumers seeking metabolic insights. Strong biotechnology investment, digital-health integration, clinical research, and regulatory development are expected to support continued commercialization.

Europe presents substantial opportunities as healthcare systems emphasize preventive care, digital health, patient-centered monitoring, and improved diabetes management. Adoption of wearable glucose technologies is supported by established healthcare infrastructure, increasing digital-health investment, and demand for less burdensome monitoring methods. European technology developers are also advancing sensor miniaturization, spectroscopy, biosensing, and AI-based interpretation, creating an ecosystem for next-generation non-invasive platforms. Expansion of connected-care models and remote patient monitoring can improve integration between glucose-monitoring devices, smartphones, healthcare professionals, and digital therapeutics. Regulatory compliance and clinical validation remain important considerations, but increasing healthcare digitization and demand for continuous metabolic information should support long-term market development.

Key Trends and Drivers

The Rise of Contactless Glucose Intelligence:

The market is moving toward wearable, AI-enabled, and contactless glucose sensing that integrates monitoring with broader digital-health ecosystems. Developers are combining advanced optical and electromagnetic sensing with machine learning, miniaturized electronics, smartphone connectivity, and cloud analytics to improve measurement frequency and user convenience. FDA databases show continued authorization activity for wearable and connected glucose-monitoring technologies, indicating sustained technological development. The longer-term direction is toward smaller, less intrusive devices capable of generating continuous metabolic insights while reducing dependence on conventional finger-prick or implanted sensing approaches.

The Growing Demand for Needle Free Diabetes Management:

The increasing burden of diabetes and demand for convenient glucose management are major factors supporting investment in non-invasive monitoring technologies. The CDC estimates 40.1 million Americans had diagnosed or undiagnosed diabetes and 115.2 million adults had prediabetes, creating a substantial addressable population for easier glucose assessment. Consumers and healthcare providers increasingly value frequent glucose information for understanding treatment response, dietary patterns, physical activity, and metabolic changes. Existing CGM adoption also demonstrates demand for automated monitoring, while advances in sensors, wireless connectivity, AI algorithms, and wearable electronics are improving the feasibility of transitioning toward completely non-invasive platforms.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Component
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Optical Glucose Monitoring
    • 4.1.2 Transdermal Glucose Monitoring
    • 4.1.3 Enzymatic Glucose Monitoring
    • 4.1.4 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Wearable Devices
    • 4.2.2 Non-Wearable Devices
    • 4.2.3 Continuous Glucose Monitors
    • 4.2.4 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Near-Infrared Spectroscopy
    • 4.3.2 Mid-Infrared Spectroscopy
    • 4.3.3 Raman Spectroscopy
    • 4.3.4 Photoacoustic Spectroscopy
    • 4.3.5 Fluorescence Technology
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by Component (2020-2035)
    • 4.4.1 Sensors
    • 4.4.2 Transmitters
    • 4.4.3 Receivers
    • 4.4.4 Software
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Diabetes Management
    • 4.5.2 Blood Glucose Testing
    • 4.5.3 Others
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 Smart Watches
    • 4.6.2 Smart Patches
    • 4.6.3 Handheld Devices
    • 4.6.4 Others
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Home Care Settings
    • 4.7.3 Diagnostic Centers
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Real-Time Monitoring
    • 4.8.2 Intermittent Monitoring
    • 4.8.3 Others
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Data Management Solutions
    • 4.9.2 Remote Monitoring Solutions
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Component
      • 5.2.1.5 Application
      • 5.2.1.6 Device
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Component
      • 5.2.2.5 Application
      • 5.2.2.6 Device
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Component
      • 5.2.3.5 Application
      • 5.2.3.6 Device
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Component
      • 5.3.1.5 Application
      • 5.3.1.6 Device
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Component
      • 5.3.2.5 Application
      • 5.3.2.6 Device
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Component
      • 5.3.3.5 Application
      • 5.3.3.6 Device
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Component
      • 5.4.1.5 Application
      • 5.4.1.6 Device
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Component
      • 5.4.2.5 Application
      • 5.4.2.6 Device
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Component
      • 5.4.3.5 Application
      • 5.4.3.6 Device
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Component
      • 5.4.4.5 Application
      • 5.4.4.6 Device
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Component
      • 5.4.5.5 Application
      • 5.4.5.6 Device
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Component
      • 5.4.6.5 Application
      • 5.4.6.6 Device
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Component
      • 5.4.7.5 Application
      • 5.4.7.6 Device
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Component
      • 5.5.1.5 Application
      • 5.5.1.6 Device
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Component
      • 5.5.2.5 Application
      • 5.5.2.6 Device
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Component
      • 5.5.3.5 Application
      • 5.5.3.6 Device
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Component
      • 5.5.4.5 Application
      • 5.5.4.6 Device
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Component
      • 5.5.5.5 Application
      • 5.5.5.6 Device
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Component
      • 5.5.6.5 Application
      • 5.5.6.6 Device
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Component
      • 5.6.1.5 Application
      • 5.6.1.6 Device
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Component
      • 5.6.2.5 Application
      • 5.6.2.6 Device
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Component
      • 5.6.3.5 Application
      • 5.6.3.6 Device
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Component
      • 5.6.4.5 Application
      • 5.6.4.6 Device
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Component
      • 5.6.5.5 Application
      • 5.6.5.6 Device
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Abbott Laboratories
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Dexcom
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Medtronic
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Roche
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Senseonics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 GlucoTrack
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Nemaura Medical
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Integrity Applications
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 C8 MediSensors
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 DiaMonTech
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Echo Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 GlySens
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 NovioSense
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Biolinq
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Afon Technology
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 PKvitality
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 POCTech
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 HemoCue
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 LifeScan
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Ascensia Diabetes Care
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us